Denali Therapeutics (DNLI) EBITDA (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly EBITDA of -$137.4 million for Q1 2026, up 5.65% year-over-year from -$130.0 million in Q1 2025, and little changed quarter-over-quarter from -$137.4 million in Q4 2025.
Denali Therapeutics (DNLI) EBITDA (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported EBITDA for 10 consecutive years, with -$137.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 5.65% year-over-year to -$137.4 million; the TTM figure through Mar 2026 stood at -$547.1 million (down 6.19% YoY), while the FY2025 annual figure was -$555.3 million, down 13.95% from the prior year.
- EBITDA was little changed at -$137.4 million in Q1 2026 per DNLI's latest filing, from -$137.4 million in the prior quarter.
- Across five years, EBITDA topped out at $170.5 million in Q2 2023 and bottomed at -$145.6 million in Q1 2025.
- Historically, EBITDA has averaged -$101.0 million across 5 years, with a median of -$120.8 million in 2023.
- Annual changes were most pronounced in 2023 — EBITDA jumped 377.59% — and 2024, when it slumped 168.39%.
- Denali Therapeutics' EBITDA stood at -$105.3 million in 2022, then decreased by 25.85% to -$132.6 million in 2023, then grew by 2.06% to -$129.8 million in 2024, then fell by 5.79% to -$137.4 million in 2025, then climbed by 0.01% to -$137.4 million in 2026.
- Business Quant data shows DNLI's EBITDA at -$137.4 million in Q1 2026, -$137.4 million in Q4 2025, and -$137.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -130.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -130.54 Mn |
| Mar 31, 2026 | -137.36 Mn |
| Dec 31, 2025 | -137.37 Mn |
| Sep 30, 2025 | -137.43 Mn |
| Jun 30, 2025 | -134.96 Mn |
| Mar 31, 2025 | -145.58 Mn |
| Dec 31, 2024 | -129.85 Mn |
| Sep 30, 2024 | -123.19 Mn |
| Jun 30, 2024 | -116.59 Mn |
| Mar 31, 2024 | -117.72 Mn |
| Dec 31, 2023 | -132.57 Mn |
| Sep 30, 2023 | -113.80 Mn |
| Jun 30, 2023 | 170.48 Mn |
| Mar 31, 2023 | -120.82 Mn |
| Dec 31, 2022 | -105.34 Mn |
| Sep 30, 2022 | -107.49 Mn |
| Jun 30, 2022 | -61.42 Mn |
| Mar 31, 2022 | -66.50 Mn |
| Dec 31, 2021 | -77.12 Mn |
| Sep 30, 2021 | -85.59 Mn |